Evofem Biosciences
Stock Forecast, Prediction & Price Target
Evofem Biosciences Financial Estimates
Evofem Biosciences Revenue Estimates
Evofem Biosciences EBITDA Estimates
Evofem Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $8.24M N/A | $16.83M 104.23% | $18.21M 8.20% | Avg: $193.32M Low: $193.32M High: $193.32M avg. 961.14% | Avg: $241.12M Low: $241.12M High: $241.12M avg. 24.73% | ||
Net Income
% change YoY
| $-205.19M N/A | $-76.69M 62.62% | $52.97M 169.07% | Avg: $28.29B Low: $28.29B High: $28.29B avg. 53300.68% | Avg: $56.58B Low: $56.58B High: $56.58B avg. 100.00% | ||
EBITDA
% change YoY
| $-133.14M N/A | $-93.59M 29.70% | $-17.37M 81.44% | Avg: $-111.42M Low: $-111.42M High: $-111.42M avg. -541.47% | Avg: $-138.98M Low: $-138.98M High: $-138.98M avg. -24.73% | ||
EPS
% change YoY
| -$2,931.31 N/A | -$163.19 94.43% | $10.35 106.34% | Avg: $28.75 Low: $28.75 High: $28.75 avg. 177.77% | Avg: $57.5 Low: $57.5 High: $57.5 avg. 100% | ||
Operating Expenses
% change YoY
| $170.99M N/A | $96.54M -43.53% | $27.77M -71.23% | Avg: $8.40B Low: $8.40B High: $8.40B avg. 30169.36% | Avg: $10.48B Low: $10.48B High: $10.48B avg. 24.73% | ||
FAQ
What is Evofem Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 26700.34% in 2025-2026.
We have gathered data from N/A analysts. Their low estimate is 28.29B, average is 28.29B and high is 28.29B.
What is Evofem Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 492.93% in 2025-2026.
We have gathered data from 1 analysts. Their low revenue estimate is $193.32M, average is $193.32M and high is $193.32M.
What is Evofem Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 138.88% in 2025-2026.
We have gathered data from N/A analysts. Their low earnings per share estimate is $28.75, average is $28.75 and high is $28.75.
What is the best performing analyst?
In the last twelve months analysts have been covering Evofem Biosciences stock. The most successful analyst is Yale Jen.